Skip to main content
OpenTrials
Completed

NCT Number: NCT03063515

AchE Inhibitor and Insulin

The investigator will examine the effect of a single dose of pyridostigmine, AchE inhibitor on insulin secretion in healthy subjects. Each subject will undergo an intravenous glucose tolerance test (IVGTT) where IV glucose will be administered and the glucose excursion and insulin secretion response will be evaluated by measuring insulin and glucose at different time points. The test will be carried out twice, once without and once with the administration of a single dose of Pyridostigmine on two separate days. The investigator hypothesizes that inhibiting AChE will potentiate insulin secretion.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Diabetes Research Institute

Miami, Florida, 33136, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 years and older

Exclusion criteria

  • BMI >30 Kg/m2
  • fasting glucose >100
  • Glycohemoglobin (Hemoglobin A1C) 5.7% or more
  • History of asthma
  • Use of medications that may interfere with glucose metabolism

Treatment and study plan

Pyridostigmine

Drug

single oral dose of 60 mg pyridostigmine tablet

Other names: Mestinon

Primary outcomes

  1. First phase insulin response to IV glucose infusion

    Time frame: -10, -4, 1, 2, 3, 4, 5, 6, 8, and 10 minutes

    Insulin positive incremental area under the curve and the sum of plasma insulin values at 1 minute and 3 minutes after IV glucose infusion

Secondary outcomes

  1. Glucose excursion after IV glucose infusion

    Time frame: -10, -4, 1, 2, 3, 4, 5, 6, 8, and 10 minutes

    Glucose positive incremental area under the curve

Sponsors and collaborators

Lead sponsor

University of Miami

Other

Collaborators

  • American Diabetes Association

Registry information

Official study title

Using Acetylcholinesterase Inhibitors to Promote Insulin Secretion in Human Beings

Acronym: AchE

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Feb 24, 2017
Registry last updated
Feb 27, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.